LEXINGTON, Mass., April 26 /PRNewswire-FirstCall/ -- MacroChem Corporation has announced that Robert J. DeLuccia, its president and chief executive officer, will present an update on the Company’s technologies, products and business strategy at the RedChip Small-Cap Investor Conference at the Hard Rock Hotel & Casino in Hollywood, Florida, on April 28, 2006.
In his presentation, Mr. DeLuccia will give an update on the business strategy of MacroChem, a specialty pharmaceutical company developing innovative products by capitalizing on its proprietary drug delivery technologies including SEPA(R), its patented transdermal penetration enhancer. He will also discuss the status of the company’s two clinical development stage SEPA-enhanced products: EcoNail(TM), an econazole nail lacquer for treating onychomycosis (fungal nail infections) and Opterone(R), a topical testosterone cream for treating male hypogonadism.
According to Red Chip Visibility, a division of RedChip Companies, the Conference will feature 30 Companies representing VOIP, Business Services, Oil and Gas, Telecom, Healthcare, Biotech, Consumer Services, Alternative Energy, Computer Hardware, and others. This is the first investor conference to be video streamed live. Investors all over the world will be able to see and hear presenters at the conference in real time by visiting http://www.redchip.com/visibility/conferenceMain.asp. Additionally, the video conferences will be available for 90 days following the conference on the RedChip site, http://www.redchip.com or http://www.macrochem.com.
About RedChip
RedChip has a long history of bringing research on selected small-cap companies to analysts and portfolio managers. RedChip Visibility(TM) provides small-cap companies access to both professional and individual small-cap investors by holding conferences throughout the United States, producing online corporate visibility programs, and writing company sponsored research.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company with two clinical development stage products containing our patented enhancer, SEPA(R): EcoNail(TM), to treat fungal infection of the nail and Opterone(R), to treat male hypogonadism. In addition to our SEPA technology, we are also evaluating applications for MacroDerm(TM), our patented series of polymers that impede penetration of active ingredients through the skin. For more information visit our website, http://www.macrochem.com
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled “Risk Factors” in MacroChem’s Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com
Investor/Media Contact:
Bernard Patriacca - VP/CFO
(781) 862-4003
MacroChem Corporation
CONTACT: Bernard Patriacca, VP/CFO of MacroChem, +1-781-862-4003
Web site: http://www.macrochem.com//
